An update on the considerations for patients with rheumatic disease being treated with rituximab during the COVID-19 pandemic and the potential drug treatment strategiesReview Published on 2022-10-012023-07-10 Journal: Expert opinion on pharmacotherapy [Category] COVID19(2023년), [키워드] COVID-19 Inflammatory rheumatic rituximab SARS-CoV-2 vaccination [DOI] 10.1080/14656566.2022.2131395 [Article Type] Review
Serological response to SARS-CoV-2 vaccination in patients with inflammatory rheumatic disease treated with disease modifying anti-rheumatic drugs: A cohort study and a meta-analysisArticle Published on 2022-10-012022-11-15 Journal: Joint bone spine [Category] COVID19(2023년), SARS, 진단, [키워드] acute respiratory syndrome addition Antibody Response biologic Cohort cohort study conducted coronavirus COVID-19 COVID-19 pandemic disease evaluated identify IgG antibody immune-mediated diseases impair individuals Inflammatory Inflammatory rheumatic diseases IQR leflunomide less management median age Meta-analysis methotrexate observational study Older participant Patient performed Prevalence reported rheumatic disease rituximab robust Sample size SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 vaccination SARS-CoV-2 vaccine SARS-CoV2 vaccination second vaccination seroconversion rate seroconverted serological response significantly Spike protein suggested targeted therapy Therapies therapy treated two-dose regimen vaccination Vaccine were measured [DOI] 10.1016/j.jbspin.2022.105380 PMC 바로가기
Comment on: “SARS CoV-2 vaccine AND rituximab, timing is probably a key for a better vaccine response” by Verhoeven et al. Joint Bone Spine 2021;88:105258Article Published on 2022-10-012022-11-15 Journal: Joint bone spine [Category] 진단, [키워드] Abstract B-cell bone Comment COVID-19 rituximab spine T-cell Vaccine [DOI] 10.1016/j.jbspin.2022.105408 PMC 바로가기
Severe Pancytopenia After COVID-19 Revealing a Case of Primary Bone Marrow Diffuse Large B Cell LymphomaArticle Published on 2022-09-242022-11-15 Journal: The American journal of case reports [Category] SARS, 진단, [키워드] abdominal pain absence advanced age Anemia anorexia Antibiotics B cell Blood bone Bone marrow Cell Chemotherapy Clinical deterioration Combination COVID-19 Culture Cyclophosphamide Diagnosis diarrhea died diffuse DLBCL Doxorubicin elevated fatigue Fever G-CSF granulocyte IMPROVE Infection inflammation markers initiated lymphoma malignancy management Marrow NHL Non-Hodgkin Lymphoma Pancytopenia Patient patient with COVID-19 PCR Platelet positive Prednisone Prognosis rituximab Thoracic tomography Treatment vincristine watery weight loss while White blood cell worsening [DOI] 10.12659/AJCR.937500 PMC 바로가기
Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials전신 홍반성 루푸스 또는 활동성 루푸스 신염에 대한 생물학적 약물과 감염 합병증 발생률. 대규모 임상 시험의 증거Article Published on 2022-09-232023-06-02 Journal: Frontiers in Immunology [Category] Fulltext, 대상포진, 두창, [키워드] anifrolumab Belimumab chronic kidney disease (CKD) herpes zoster Infection Lupus rituximab [DOI] 10.3389/fimmu.2022.999704 PMC 바로가기
Response to SARS-CoV-2 vaccines in patients receiving B-cell modulating antibodies for renal autoimmune diseaseArticle Published on 2022-09-142022-11-15 Journal: BMC Infectious Diseases [Category] SARS, 진단, [키워드] Adequate anti-CD20 anti-CD20 treatment antibody antibody treatment Autoimmune disease B-cell B-cells CD19 CD20 cellular cellular response clinical correlated COVID-19 depleting develop disease generate humoral immune Immunity immunization kidney modulating Patient patients receiving treatment receiving regimens Registered renal response retrospective rituximab SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine single-center timespan Treatment vaccination vaccination response [DOI] 10.1186/s12879-022-07722-7 PMC 바로가기
A meta-analysis on efficacy and safety of rituximab for neuromyelitis optica spectrum disordersSystematic Review and Meta-Analysis Published on 2022-09-092024-09-04 Journal: Medicine [Category] 대상포진, [키워드] Meta-analysis Neuromyelitis Optica Neuromyelitis optica spectrum disorders rituximab [DOI] 10.1097/MD.0000000000030347 PMC 바로가기 [Article Type] Systematic Review and Meta-Analysis
Treatment with obinutuzumab leads to worse outcomes in haematological patients diagnosed with Omicron variant COVID-19오비누투주맙 치료는 오미크론 변이 코로나19로 진단받은 혈액학적 환자에서 더 나쁜 결과를 가져온다Article Published on 2022-09-012022-09-11 Journal: British Journal of Haematology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] Abstract anti-CD20 anti-CD20 monoclonal antibodies COVID-19 diagnosed haematological malignancies monoclonal obinutuzumab omicron outcome Patient rituximab SARS-CoV-2 SARS-COV-2 infection variant [DOI] 10.1111/bjh.18315 PMC 바로가기 [Article Type] Article
Reactivation of EBV and CMV in Severe COVID-19-Epiphenomena or Trigger of Hyperinflammation in Need of Treatment? A Large Case Series of Critically ill Patients심각한 COVID-19-Epiphenomena에서 EBV 및 CMV의 재활성화 또는 치료가 필요한 Hyperinflammation의 트리거? 중환자의 대규모 사례 시리즈Article Published on 2022-09-012022-09-11 Journal: Journal of Intensive Care Medicine [Category] 치료기술, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 analyzed ARDS Chain Reaction Characteristics Clinical deterioration CMV cohort study comparable connection control group coronavirus Corticosteroid Course COVID-19 Critically ill Critically ill patient critically ill patients cytomegalovirus decrease described Diagnosis disease EBV Epstein-Barr virus Follow-up analysis Ganciclovir high risk hyperinflammation ICU in viral incidence increased mortality initiation of treatment intensive care intensive care unit majority Non-COVID-19 non-COVID-19 patient Non-COVID-19 patients outcome Patient polymerase chain polymerase chain reaction Reactivation remains uncertain retrospective rituximab SARS-CoV-2 screened Sepsis sepsis patient Sery severe acute respiratory syndrome Coronavirus severe COVID-19 single-center survived systemic corticosteroid treated Treatment Trigger Viral load viral reactivation virus with COVID-19 [DOI] 10.1177/08850666211053990 PMC 바로가기 [Article Type] Article
Glucocorticoids’ treatment impairs the medium-term immunogenic response to SARS-CoV-2 mRNA vaccines in Systemic Lupus Erythematosus patientsArticle Published on 2022-08-302022-11-15 Journal: Scientific Reports [Category] SARS, 진단, [키워드] administration Analysis Complete cross-sectional declining decrease evaluate groups help highest immunogenic immunosuppressive drug impacted impair individual Limited Lupus mRNA mRNA vaccine neutralizing antibody Patient patients protocol recommendation reduction in regimen Rheumatic diseases rituximab SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine SLE SLE patient SLE patients subject systemic therapy titre treated Treatment vaccination Vaccine [DOI] 10.1038/s41598-022-18996-x PMC 바로가기